RBC Raises Apogee Price Target to $135
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
RBC Capital analyst Brian Abrahams raised the firm's price target on Apogee Therapeutics (APGE) to $135 from $97 and keeps a Sector Perform rating on the shares after AbbVie (ABBV) announced its acquisition of Apogee for $135.11 per share in cash or $10.9B. The firm's higher price target reflects the deal price and likelihood the deal ultimately goes through, the analyst tells investors in a research note, adding that while competitive offers are possible as there are a number of key players in the space, Apogee likely ran a process that would have already incorporated other potential external interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to fall
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 133.500
Low
83.00
Averages
105.67
High
137.00
Current: 133.500
Low
83.00
Averages
105.67
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jefferies Recommends Low-Stress Quality Stocks Amid AI Volatility
- AI Investment Risks: Jefferies highlights increasing market volatility due to concerns over AI investments, recommending that investors hold low-stress quality stocks to navigate potential risks, particularly as overinvestment in AI could lead to market corrections.
- Quality Company Screening: The high-quality companies recommended by Jefferies must have market values exceeding $10 billion, solid fundamentals, and long-term free cash flow yields above 3%, while also being valued at less than 20 times expected earnings over the next year to ensure stability in uncertain markets.
- AbbVie Standout Performance: AbbVie is rated as a top-quality stock by Jefferies, with an expected compound annual growth rate of nearly 28% for 2026-2027 and a free cash flow yield of 5.2%, reflecting a strong growth and cash flow combination, reporting $15 billion in global net revenues in Q1, largely driven by a $7.3 billion immunology portfolio.
- Cautious Outlook for Netflix: Although Netflix also received a high-quality score in Jefferies' model, forecasting a 13% revenue growth for Q2, its stock fell 10% in mid-April due to concentrated content spending in the first half, indicating market caution regarding its future performance.
See More
iShares Core High Dividend ETF Outperforms S&P 500
- Market Outperformance: The iShares Core High Dividend ETF has risen over 15% this year, significantly outperforming the S&P 500's 9% increase, highlighting its investment advantage in high-yield stocks and attracting more income-seeking investors.
- Quality Stock Selection: This ETF tracks an index of high-yield U.S. dividend stocks, currently holding 75 stocks with an annual dividend yield of 2.9%, nearly three times that of the S&P 500, indicating its strong competitive edge in dividend investing.
- Sector Drivers: The fund's high exposure to energy stocks, particularly ExxonMobil and Chevron, which are up 14% and 11% respectively, has significantly boosted its performance, while strong gains from healthcare stocks like AbbVie and Merck have also contributed to its growth.
- Growth Potential: Since its inception in 2011, the iShares Core High Dividend ETF has delivered over 10% annualized returns, and with its focus on high-quality dividend stocks, it is expected to continue providing stable income and growth opportunities for investors.
See More
iShares Core High Dividend ETF Surges Over 15% Year-to-Date
- High-Yield Stock Advantage: The iShares Core High Dividend ETF has surged over 15% this year, primarily benefiting from its higher exposure to high-yield energy stocks, particularly ExxonMobil and Chevron, which have risen 14% and 11% respectively, thus driving the fund's overall performance.
- Healthcare Stock Contribution: The ETF has also gained from its significant allocation to healthcare stocks, notably AbbVie and Merck, with AbbVie shares up over 14% and Merck up over 23%, indicating that high-quality dividend stocks can deliver substantial total returns.
- Dividend Yield Comparison: The iShares Core High Dividend ETF currently boasts a dividend yield of 2.9%, nearly three times the S&P 500's yield of 1.1%, highlighting its advantage in providing stable cash flow, which attracts income-seeking investors.
- Strong Long-Term Performance: Since its inception in 2011, the ETF has delivered over 10% annualized returns over the past one, three, and five years, indicating success in its investment strategy focused on high-quality dividend stocks, and it is expected to continue providing strong returns in the future.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating AvalonBay Communities, Inc. (NYSE:AVB) regarding its sale to Equity Residential, which involves exchanging each share of AvalonBay for 2.793 shares of Equity Residential, potentially impacting shareholder rights.
- Transaction Details: Open Lending Corporation (NASDAQ:LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, and Halper Sadeh LLC is assessing the legality of this transaction, which may not serve the best interests of shareholders.
- Cash Acquisition: Apogee Therapeutics, Inc. (NASDAQ:APGE) is being sold to AbbVie for $135.11 per share in cash, and Halper Sadeh LLC may seek increased compensation and disclosures to ensure shareholder rights are upheld.
- Legal Support: Taylor Morrison Home Corporation (NYSE:TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per share in cash, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their rights and options.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ:APGE) regarding its sale to AbbVie at $135.11 per share, raising concerns about potential violations of shareholder rights and financial benefits unavailable to ordinary shareholders.
- M&A Scrutiny: Identiv, Inc. (NASDAQ:INVE) is selling its IoT business assets and Thai subsidiary to Trackonomy Systems, Inc., which may impact shareholder rights, prompting Halper Sadeh LLC to encourage shareholders to explore their rights and options.
- Merger Review: The merger between Colony Bankcorp, Inc. (NYSE:CBAN) and First Reliance Bancshares, Inc. is under scrutiny, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
- Legal Services Offered: Halper Sadeh LLC provides legal services on a contingency fee basis, aiming to advocate for investors affected by securities fraud and corporate misconduct, highlighting its track record in corporate reform and recovering funds for defrauded investors.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF has a 52-week low of $83.02 and a high of $160.82, with the latest trade at $159.31, indicating strong performance near its peak and reflecting ongoing market interest in the biotechnology sector.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities to optimize investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights significant inflows (new units created) or outflows (old units destroyed), which directly affects the underlying holdings of the ETF and consequently impacts the market performance of related stocks.
See More
Jefferies Recommends Low-Stress Quality Stocks Amid AI Volatility
- AI Investment Risks: Jefferies highlights increasing market volatility due to concerns over AI investments, recommending that investors hold low-stress quality stocks to navigate potential risks, particularly as overinvestment in AI could lead to market corrections.
- Quality Company Screening: The high-quality companies recommended by Jefferies must have market values exceeding $10 billion, solid fundamentals, and long-term free cash flow yields above 3%, while also being valued at less than 20 times expected earnings over the next year to ensure stability in uncertain markets.
- AbbVie Standout Performance: AbbVie is rated as a top-quality stock by Jefferies, with an expected compound annual growth rate of nearly 28% for 2026-2027 and a free cash flow yield of 5.2%, reflecting a strong growth and cash flow combination, reporting $15 billion in global net revenues in Q1, largely driven by a $7.3 billion immunology portfolio.
- Cautious Outlook for Netflix: Although Netflix also received a high-quality score in Jefferies' model, forecasting a 13% revenue growth for Q2, its stock fell 10% in mid-April due to concentrated content spending in the first half, indicating market caution regarding its future performance.
See More
iShares Core High Dividend ETF Outperforms S&P 500
- Market Outperformance: The iShares Core High Dividend ETF has risen over 15% this year, significantly outperforming the S&P 500's 9% increase, highlighting its investment advantage in high-yield stocks and attracting more income-seeking investors.
- Quality Stock Selection: This ETF tracks an index of high-yield U.S. dividend stocks, currently holding 75 stocks with an annual dividend yield of 2.9%, nearly three times that of the S&P 500, indicating its strong competitive edge in dividend investing.
- Sector Drivers: The fund's high exposure to energy stocks, particularly ExxonMobil and Chevron, which are up 14% and 11% respectively, has significantly boosted its performance, while strong gains from healthcare stocks like AbbVie and Merck have also contributed to its growth.
- Growth Potential: Since its inception in 2011, the iShares Core High Dividend ETF has delivered over 10% annualized returns, and with its focus on high-quality dividend stocks, it is expected to continue providing stable income and growth opportunities for investors.
See More
iShares Core High Dividend ETF Surges Over 15% Year-to-Date
- High-Yield Stock Advantage: The iShares Core High Dividend ETF has surged over 15% this year, primarily benefiting from its higher exposure to high-yield energy stocks, particularly ExxonMobil and Chevron, which have risen 14% and 11% respectively, thus driving the fund's overall performance.
- Healthcare Stock Contribution: The ETF has also gained from its significant allocation to healthcare stocks, notably AbbVie and Merck, with AbbVie shares up over 14% and Merck up over 23%, indicating that high-quality dividend stocks can deliver substantial total returns.
- Dividend Yield Comparison: The iShares Core High Dividend ETF currently boasts a dividend yield of 2.9%, nearly three times the S&P 500's yield of 1.1%, highlighting its advantage in providing stable cash flow, which attracts income-seeking investors.
- Strong Long-Term Performance: Since its inception in 2011, the ETF has delivered over 10% annualized returns over the past one, three, and five years, indicating success in its investment strategy focused on high-quality dividend stocks, and it is expected to continue providing strong returns in the future.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating AvalonBay Communities, Inc. (NYSE:AVB) regarding its sale to Equity Residential, which involves exchanging each share of AvalonBay for 2.793 shares of Equity Residential, potentially impacting shareholder rights.
- Transaction Details: Open Lending Corporation (NASDAQ:LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, and Halper Sadeh LLC is assessing the legality of this transaction, which may not serve the best interests of shareholders.
- Cash Acquisition: Apogee Therapeutics, Inc. (NASDAQ:APGE) is being sold to AbbVie for $135.11 per share in cash, and Halper Sadeh LLC may seek increased compensation and disclosures to ensure shareholder rights are upheld.
- Legal Support: Taylor Morrison Home Corporation (NYSE:TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per share in cash, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their rights and options.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ:APGE) regarding its sale to AbbVie at $135.11 per share, raising concerns about potential violations of shareholder rights and financial benefits unavailable to ordinary shareholders.
- M&A Scrutiny: Identiv, Inc. (NASDAQ:INVE) is selling its IoT business assets and Thai subsidiary to Trackonomy Systems, Inc., which may impact shareholder rights, prompting Halper Sadeh LLC to encourage shareholders to explore their rights and options.
- Merger Review: The merger between Colony Bankcorp, Inc. (NYSE:CBAN) and First Reliance Bancshares, Inc. is under scrutiny, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
- Legal Services Offered: Halper Sadeh LLC provides legal services on a contingency fee basis, aiming to advocate for investors affected by securities fraud and corporate misconduct, highlighting its track record in corporate reform and recovering funds for defrauded investors.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF has a 52-week low of $83.02 and a high of $160.82, with the latest trade at $159.31, indicating strong performance near its peak and reflecting ongoing market interest in the biotechnology sector.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities to optimize investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights significant inflows (new units created) or outflows (old units destroyed), which directly affects the underlying holdings of the ETF and consequently impacts the market performance of related stocks.
See More
